Bill Sibold, Madrigal Pharmaceuticals CEO
August 7, 2024 07:45 AM EDTUpdated 11:21 AM
Pharma
Marketing

Up­dat­ed: Madri­gal fi­nal­ly re­veals first wave of sales for MASH drug Rezd­if­fra

Nicole DeFeudis

Editor

Madri­gal Phar­ma­ceu­ti­cals is “off to a strong start” with its re­cent­ly ap­proved MASH drug Rezd­if­fra, CEO Bill Si­bold said on Wednes­day. The com­pa­ny pulled …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times